Modifications in coagulation parameters induced by treatment associating urokinase (2000 u CTA/kg/h) with heparin.
D001777:Blood Coagulation / Q000187:drug effects*; D004359:Drug Therapy, Combination; D010450:Endopeptidases / Q000008:administration & dosage*; D005338:Fibrin Fibrinogen Degradation Products; D005340:Fibrinogen; D006493:Heparin / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D010690:Phlebography; D010958:Plasminogen; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage* / Q000627:therapeutic use; D000515:alpha 1-Antitrypsin; D000979:alpha-2-Antiplasmin
D005338:Fibrin Fibrinogen Degradation Products; D000515:alpha 1-Antitrypsin; D000979:alpha-2-Antiplasmin; D005340:Fibrinogen; D010958:Plasminogen; D006493:Heparin; D010450:Endopeptidases; D014568:Urokinase-Type Plasminogen Activator